Author | Tatsuzo Tanabe, MD, PhD


UFT and Mitomycin Plus Tamoxifen for Stage II, ER-Positive Breast Cancer

July 01, 1999

ByYoshinobu Hata, MD, PhD|Junichi Uchino, MD, PhD|Kazuaki Asaishi, MD, PhD|Yoshihiko Kubo, MD, PhD|Michio Mito, MD, PhD|Tatsuzo Tanabe, MD, PhD|Masami Ogita, MD, PhD|Koichi Hirata, MD

A trial was designed to examine the combination of UFT and mitomycin (Mutamycin) plus tamoxifen (Nolvadex) as postoperative adjuvant therapy in the treatment of patients with stage II, estrogen receptor (ER)-positive